A-Site and B-Site Order in (Na\u3csub\u3e1/2\u3c/sub\u3eLa\u3csub\u3e1/2\u3c/sub\u3e)(Mg\u3csub\u3e1/3\u3c/sub\u3eNb\u3csub\u3e2/3\u3c/sub\u3e)O\u3csub\u3e3\u3c/sub\u3e Perovskite

(Na1/2La1/2)(Mg1/3Nb2/3)O3 undergoes a series of phase transitions that involve cation order on the A- and B-sites of the parent perovskite structure. At high temperatures both sites contain a random distribution of cations; below 1275°C a 〈111〉 layering of Mg and Nb leads to the formation of a 1:2 ordered structure with a monoclinic supercell. A second transition was observed at 925°C, where the Na and La cations order onto alternate A-site positions along the 〈001〉 direction of the parent subcell. By quenching samples from above 1275°C to preserve the disorder on the B-site, a fourth variant of this compound was obtained by inducing A-site order through a subsequent anneal at 900°C. Although the changes in structure do not produce significant alterations in the relative permittivity (εr ~ 35), they do have a significant effect on the value of the temperature coefficient of the capacitance

Soapbox Session D

Humanities Heart (Jeffrey Suttles) From Four-Color to Inclusive: race and gender in contemporary superhero comics (James Cosper) You Look Disgusting : A YouTube Beauty Guru\u27s Response to Comments About Beauty and Ugliness (Emily Tarvin) Tomi Lahren: White Power Barbie (Rachel Molko

Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial

Introduction Direct-to-family clinical trials efficiently provide data while reducing the participation burden for children and their families. Although these trials can offer significant advantages over traditional clinical trials, the process of designing and implementing direct-to-family studies is poorly defined, especially in children with rheumatic disease. This paper provides lessons learnt from the design and implementation of a self-controlled, direct-to-family pilot trial aimed to evaluate the effects of a medication management device on adherence to hydroxychloroquine in paediatric SLE.Methods Several design features accommodate a direct-to-family approach. Participants meeting eligibility criteria from across the USA were identified a priori through a disease registry, and all outcome data are collected remotely. The primary outcome (medication adherence) is evaluated using electronic medication event-monitoring, plasma drug levels, patient questionnaires and pill counts. Secondary and exploratory endpoints include (1) lupus disease activity measured by a remote SLE Disease Activity Index examination and the Systemic Lupus Activity Questionnaire; and (2) hydroxychloroquine pharmacokinetics and pharmacodynamics. Recruitment of the initial target of 20 participants was achieved within 10 days. Due to initial recruitment success, enrolment was increased to 26 participants. Additional participants who were interested were placed on a waiting list in case of dropouts during the study.Discussion and dissemination Direct-to-family trials offer several advantages but present unique challenges. Lessons learnt from the protocol development, design, and implementation of this trial will inform future direct-to-family trials for children and adults with rheumatic diseases. Additionally, the data collected remotely in this trial will provide critical information regarding the accuracy of teleresearch in lupus, the impact of adherence to hydroxychloroquine on disease activity and a pharmacokinetic analysis to inform paediatric-specific dosing of hydroxychloroquine.Trial registration number ClinicalTrials.gov Registry (NCT04358302)